AXL signaling in cancer: from molecular insights to targeted therapies

AXL, a member of the TAM receptor family, has emerged as a potential target for advanced-stage human malignancies. It is frequently overexpressed in different cancers and plays a significant role in various tumor-promoting pathways, including cancer cell proliferation, invasion, metastasis, epithelial-mesenchymal transition (EMT), angiogenesis, stemness, DNA damage response, acquired therapeutic resistance, immunosuppression, and inflammatory responses. Beyond oncology, AXL also facilitates viral infections, including SARS-CoV-2 and Zika highlighting its importance in both cancer and virology. In preclinical models, small-molecule kinase inhibitors targeting AXL have shown promising anti-tumorigenic potential.…

• FF
  Foundation for the National Institutes of Health

  Award: RO1 CA193675 and RO1 CA222355
• DC
  Dana-Farber Cancer Institute
• DC
  Dana-Farber/Harvard Cancer Center

  Awards: 5P50CA101942-18, 2P50CA101942-16, 5P50CA101942, 5P30CA006516-56, 5P30CA006516, 2P50CA101942-16 and 5P30CA006516-56
• DO
  Department of Biotechnology, Ministry of Science and Technology, India
• NI
  National Institutes of Health

  Award: 5P30CA006516